Medical Weight Loss Clinics: GLP-1 Providers and Costs by State

Across the 18 cash-pay clinics that publish a monthly price with the medication included, VitalityScout verified a median of $262.50/mo (range $100–$1000/mo, verified July 2026). Membership-only programs that bill the medication separately post lower headline numbers, from $65/mo across 8 clinics, and are not the same product. Most clinics publish no price at all and quote only after a paid consult. Confirm the current number and exactly what it includes before you enroll.

No clinic or site can name a best GLP-1 for you, and none can promise a result. What you can check is what each product is actually approved to treat. Wegovy (semaglutide injection) is FDA-approved for chronic weight management and to reduce the risk of major adverse cardiovascular events. Zepbound (tirzepatide) is FDA-approved for chronic weight management and for moderate-to-severe obstructive sleep apnea in adults with obesity. Saxenda (liraglutide) is FDA-approved for weight management. Ozempic and Rybelsus (semaglutide), Mounjaro (tirzepatide), and Victoza (liraglutide) are FDA-approved for type 2 diabetes; prescribing them for weight loss is off-label prescribing, not an approved use. A licensed prescriber decides what is appropriate after reviewing your history.

The injectable medicines carrying an FDA-approved weight-management indication include Wegovy (semaglutide), Zepbound (tirzepatide), and Saxenda (liraglutide). Ozempic (semaglutide) and Mounjaro (tirzepatide) contain the same molecules but are labeled for type 2 diabetes, so using them for weight loss is off-label prescribing. Compounded semaglutide and tirzepatide injections are not FDA-approved at all. Read each product label before you compare programs.

No. Compounded semaglutide and tirzepatide are not FDA-approved, and FDA states that unapproved versions do not undergo its review for safety, effectiveness, and quality before they are marketed. FDA has received adverse event reports, some requiring hospitalization, that may be related to dosing errors with compounded injectable semaglutide, including patients and health care professionals miscalculating doses. FDA recommends compounded drugs only for patients whose medical needs cannot be met by an FDA-approved drug, with a prescription filled at a state-licensed pharmacy.

Both routes exist and both require a prescription from a licensed clinician. Telehealth programs run an intake, review your history and labs, and ship medication to your door. In-person clinics add physical exams, in-office labs, and body-composition tracking. Availability, included labs, and what the monthly fee covers vary by state and by program, which is why the verified prices on this page span a wide range. Browse in-person clinics by state below, or compare national GLP-1 telehealth providers on our GLP-1 page.

The FDA labels specify a stepwise titration: treatment starts at a low weekly dose and steps up on a fixed schedule toward a maintenance dose, so the medicine is introduced gradually. That schedule is what the manufacturer submitted and FDA approved. It is not a personal plan. Your prescriber determines your starting dose, whether and when to step up, and whether to stay lower. Do not start, change, split, or combine doses on your own, and do not convert a dose from one GLP-1 to another. Our dosing guides report the label schedules for semaglutide and tirzepatide for educational reference only.